South Korea kept Neuronata-R on the market. Now CorestemChemon’s harder test begins
South Korea keeps Neuronata-R available after Phase 3 review, but manufacturing, patient selection and a delayed U.S. filing remain decisive tests ahead.
Pharma & Biotech